Momenta Ventures Invests in IoT Connectivity Company Thingstream
Thingstream, a leading provider of IoT Connectivity-as-a-Service, announces an investment from Momenta Ventures, a Digital Industry venture investment firm.
With Thingstream successfully separating from its incubating company Myriad Group earlier this year, Momenta Ventures’ investment marks a significant milestone to scale growth. “We are happy to have Momenta Ventures on-board. Their deep industry knowledge about Digital Industry and their commitment to Low Power, Wide Area Networks (LPWAN) is unique. Momenta’s investment in Thingstream is a significant affirmation of our mission to connect the enterprise via LPWAN, unlocking the potential of IoT”, says Philipp Bolliger, CEO Thingstream.
Thingstream offers simple to use connectivity solutions, supporting asset tracking, remote monitoring and related Industrial IoT use cases. Its solutions support low-power, secure connectivity with coverage across more than 190 countries. Thingstream’s holistic approach to connectivity accelerates enterprise projects by removing common barriers to collecting data from IoT devices thus unlocking the promise of IoT for enterprise customers worldwide. Thingstream supports connectivity through license spectrum cellular technologies today and are in the process of adding unlicensed LPWAN technologies including LoRaWAN to their offering.
Momenta Ventures’ Managing Director Ken Forster states “We’re excited to be supporting Thingstream in their journey to connect industrial devices world-wide. As practitioners in Digital Industry, we see reliable, low-cost connectivity as a critical enabler for enterprise IoT solutions. We believe that ubiquitous LPWAN devices, networks and applications, across licensed and unlicensed spectrum, will drive dramatic growth in scope and volume in the next few years.” Mr. Forster continues, “We believe our investment in Thingstream will further accelerate this LPWAN trend in Digital Industry, thus complementing our other ecosystem investments”.
Thingstream is preparing for a Series A investment and will be exhibiting at the premier event for the Industrial IoT: IoT Solutions World Congress in Barcelona (29-31 October), where they plan to make several key industry announcements.
About Thingstream
Thingstream is a leading provider of Connectivity-as-a-Service for the Internet of Things (IoT) applications. Thingstream’s intelligent Global Connectivity Platform provides low power, low cost, ubiquitous IoT connectivity via MQTT and works in over 190 countries already today. The secure, out-of-the-box IoT connectivity solution leverages both the globally-available GSM network as well as private LoRaWAN implementation to offer immediate, global IoT connectivity that no other low power connectivity provider can today. Thingstream specialises in helping simplify IoT connectivity, reducing costs and operational overheads in the delivery of an intelligent network of connected things. For more information visit https://thingstream.io.
About Momenta Ventures
Momenta Ventures is the investment arm of Momenta Partners, the leading Digital Industry Growth Partner firm. Led by deep operating practitioners with strong entrepreneurial and corporate track-records, Momenta Ventures has made over 30 investments with notable exits to SAP, PTC and Husqvarna Group. Momenta Ventures runs two Digital Industry ecosystem funds, focused on seed and Series A investments in Digital Energy, Manufacturing, Smart Spaces and Supply Chain globally. The most recent fund focuses on Digital Industry innovation powered by LPWAN, specifically LoRa and LoRaWAN. For more information visit https://momenta.vc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005492/en/
Contact information
Press contact for Thingstream:
Dan Walsh
MUSTARD PR
dan@mustardpr.com
+44 (0) 7827 816 971
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release
CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom